| Literature DB >> 33961197 |
Mathilde Coquaz-Garoudet1, Dominique Ploin1,2, Robin Pouyau1, Yoav Hoffmann3, Julien-Frederic Baleine4, Benoît Boeuf5, Hugues Patural6, Anne Millet7, Marc Labenne8, Renaud Vialet9, Didier Pinquier10, Marie Cotillon10, Jérôme Rambaud11, Etienne Javouhey12,13.
Abstract
BACKGROUND: Malignant pertussis (MP) affects young infants and is characterized by respiratory distress, perpetual tachycardia and hyperleukocytosis up to 50 G/l, leading to multiple organ failure and death in 75% of cases. Leukodepletion may improve prognosis. A therapeutic strategy based on leukodepletion and extracorporeal life support (ECLS) according to different thresholds of leucocytes has been proposed by Rowlands and colleagues. We aimed at identifying factors associated with death and assess whether the respect of the Rowlands' strategy is associated with survival.Entities:
Keywords: Hyperleukocytosis; Leukodepletion; Malignant pertussis; Pediatric intensive care; Risk factors of death
Year: 2021 PMID: 33961197 PMCID: PMC8105476 DOI: 10.1186/s13613-021-00856-y
Source DB: PubMed Journal: Ann Intensive Care ISSN: 2110-5820 Impact factor: 6.925
Patient characteristics at the time of emergency department admission and at PICU admission
| Non-survivors ( | Survivors ( | All patients | ||
|---|---|---|---|---|
| A: At emergency department admission | ||||
| Girl, | 5 (56) | 6 (43) | 0.7 | 11 (48) |
| Postmenstrual age, weeks, median [IQR] | 37 [36–39] | 38 [35–40] | 0.6 | 38 [36–40] |
| Preterm, | ||||
| < 37 weeks | 2 (22) | 5 (36) | 0.6 | 7 (30) |
| < 33 weeks | 0 (0) | 2 (14) | 0.5 | 2 (9) |
| Birth weight, kg, median [IQR] | 2.5 [2.3–3.0] | 2.9 [2.6–3.6] | 0.1 | 2.9 [2.5–3.5] |
| Age, days, median [IQR] | 31 [20–54] | 57 [32–74] | 0.1 | 41 [28–69] |
| Weight, kg, median [IQR] | 3.5[2.9–4.0] | 3.8 [3.1–5.9] | 0.2 | 3.6 [3–4.6] |
| Heart rate, bpm, median [IQR] | 176 [164–195] | 169 [155–179] | 0.3 | 170 [161–195] |
| Respiratory failure, | 8 (89) | 12 (86) | 0.6 | 20 (87) |
| Sodium level, mmol/l, median [IQR] | 138 [137–139] | 135 [134–138] | 0.1 | 137 [135–139] |
| C-reactive protein, mg, median [IQR] | 67 [20–160] | 4 [0–18] | 0.02 | 10 [0–51] |
| pH, median [IQR] | 7.25 [7.19–7.32] | 7.32 [7.25–7.35] | 0.1 | 7.29 [7.23–7.33] |
| pCO2, kPa, median [IQR] | 8.2 [7.0–10.5] | 7.4 [6.4–8.5] | 0.4 | 7.5 [7.0–9.0] |
| WBC count, G/l, median [IQR] | 26 [19–50] | 36 [20–58] | 0.6 | 32 [19–55] |
| Neutrophil count, G/l, median [IQR] | 8 [6–14] | 7 [5–13] | 0.6 | 8 [5–13] |
| Lymphocyte count, G/l, median [IQR] | 17 [10–30] | 23 [12–39] | 0.5 | 22 [10–37] |
| Lymphocyte/neutrophil ratio < 1, | 1 (11) | 1 (7) | 1 | 2 (9) |
| B: At the time of transfer/admission to PICU | ||||
| PELOD score, median [IQR] | 11 [10–20] | 10 [1–14] | 0.25 | 11 [1–20] |
| Heart rate, bpm, median [IQR] | 193 [181–202] | 179 [171–199] | 0.25 | 185 [174–200] |
| Need for emergency intubation before PICU admission, | 3 (33) | 3 (21) | 0.44 | 6 (26) |
| SpO2/FiO2 ratio, median [IQR] | 426 [259–452] | 384 [227–452] | 0.87 | 384 [238–452] |
| pH, median [IQR] | 7.29 [7.22–7.35] | 7.31 [7.22–7.36] | 0.51 | 7.30 [7.23–7.36] |
| pCO2 kPa, median [IQR] | 7.3 [6.4–9.4] | 7.19 [6.34–8.5] | 0.68 | 7.3 [6.4–9.0] |
| Sodium level, mmol/l, median [IQR] | 129 [126–135] | 135 [131–136] | 0.07 | 134 [128–136] |
| Lactate, mmol/l, median [IQR] | 2 [2–4] | 2 [1–3] | 0.29 | 2 [1–3] |
| WBC count, G/l, median [IQR] | 52 [38–91] | 54 [41–60] | 0.6 | 53 [42–81] |
IQR interquartile range; pCO partial pressure of carbon dioxide; PELOD pediatric logistic organ dysfunction; SpO/FiO ratio pulse oximetry saturation/fraction of inspiratory oxygen; WBC white blood cell
Patient characteristics during PICU stay according to outcome
| Non-survivors | Survivors | All patients | ||
|---|---|---|---|---|
| Cardiovascular failure, | 9 (100) | 5 (36) | 0.003 | 14 (61) |
| Pulmonary hypertension, | 9 (100) | 4 (29) | 0.002 | 13 (56) |
| Kidney failure, | 8 (89) | 3 (21) | 0.003 | 11 (48) |
| Anuria, | 9 (100) | 3 (21) | < 0.001 | 12 (52) |
| Neurological failure, | 3 (33) | 6 (43) | 1 | 9 (39) |
| Liver failure, | 5 (56) | 2 (14) | 0.049 | 7 (30) |
| Documented bacterial superinfection, | 6 (67) | 8 (57) | 1 | 14 (61) |
| Documented viral co-infection, | 4 (44) | 5 (36) | 1 | 9 (39) |
| Hematological failure, | 5 (56) | 2 (14) | 0.02 | 7 (30) |
| Secondary thrombopenia, | 7 (78) | 6 (43) | 0.19 | 13 (57) |
| Minimal sodium level, mmol/l, median [IQR] | 122 [119–125] | 131 [129–135] | 0.003 | 130 [122–135] |
| Maximal lactate, mmol/l, median [IQR] | 9 [3–16] | 3 [2–4] | 0.02 | 3 [2–9] |
| Minimal pH, median [IQR] | 7.05 [6.8–7.1] | 7.24 [7.17–7.32] | 0.002 | 7.18 [7.05–7.26] |
| Maximal pCO2, kPa, median [IQR] | 9.1 [8.7–12.3] | 8.3 [7.0–11.0] | 0.25 | 9.0 [7.7–11.5] |
| Maximal creatinine, µmol/l, median [IQR] | 81 [49–110] | 27 [23–51] | 0.002 | 40 [25–82] |
| Maximal C-reactive protein, mg/l, median [IQR] | 203 [135–237] | 90 [7–205] | 0.11 | 135 [30–217] |
| Maximal procalcitonin, µg/l, median [IQR] | 19.0 [6.3–23.7] | 1.0 [0.2–4.3] | 0.012 | 3.3 [0.5–19.3] |
| WBC growth, G/l/day, median [IQR] | 21 [10–28] | 6 [3–7] | 0.007 | 6 [3–17] |
| Maximal WBC count, G/l, median [IQR] | 88 [63–95] | 65 [53–81] | 0.12 | 71 [56–91] |
| Maximal neutrophils, G/l, median [IQR] | 41 [23–47] | 25 [16–37] | 0.14 | 26 [18–46] |
| Maximal lymphocytes, G/l, median [IQR] | 33 [26–34] | 33 [28–39] | 0.83 | 32 [28–37] |
| Lymphocyte/neutrophil ratio < 1, | 8 (89) | 3 (21) | 0.003 | 12 (52) |
aStenotrophomonas maltophilia (1), SAMS (4), Escherichia coli (2), Klebsiella pneumoniae + Citrobacter koseri (1), Streptococcus pneumoniae (2), Enterobacter cloacae (1), other GNB (1), Haemophilus influenzae (1), Corynebacterium (1) were identified through tracheal (1), nasopharyngeal (7), blood culture (5), and bronchoalveolar lavage (1) samples
bRhinovirus (3), Picornavirus (3), Bocavirus (1), Influenza B (1), RSV (3), were identified through nasopharyngeal samples (8)
IQR interquartile range; pCO partial pressure of carbon dioxide; PELOD pediatric logistic organ dysfunction; PICU pediatric intensive care unit; SpO/FiO ratio pulse oximetry saturation/fraction of inspiratory oxygen; WBC white blood cell
Therapeutics used during PICU stay, and compliance with Rowlands’ algorithm [20]
| Non-survivors ( | Survivors ( | All patients ( | ||
|---|---|---|---|---|
| Invasive ventilation, | 9 (100) | 12 (86) | 0.048 | 21 (91) |
| Treatment of pulmonary hypertension, | ||||
| Inhaled nitric oxide (INO) | 6 (67) | 3 (21) | 0.07 | 9 (39) |
| Sildenafil as an add-on to INO | 1 (11) | 2 (14) | 1 | 3 (13) |
| Renal replacement therapy, | 4 (44) | 2 (14) | 0.16 | 6 (26) |
| Corticosteroids, | 1 (11) | 5 (36) | 0.34 | 6 (26) |
| Broad-spectrum antibiotics | 9 (100) | 10 (71) | 0.13 | 19 (83) |
| Leukodepletion, | 3 (33) | 7 (50) | 0.7 | 10 (43) |
| Exchange transfusion, | 2 (22) | 6 (42) | 8 (35) | |
| Leukopheresis, | 1 (11) | 1 (7) | 2 (8) | |
| ECLS, | 6 (67) | 1 (7) | 0.05 | 7 (30) |
| Compliance with Rowlands’ algorithm, | 0 (0) | 12 (86) | < 0.001 | 12 (52) |
ECLS extracorporeal life support; PICU pediatric intensive care unit
Fig. 1Boxplot of WBC growth according to the patient outcome. Box and whiskers plot quartiles and the bold band inside the box is the median. The ends of the whiskers represent the minimum and maximum of all of the data, with the exception of the two outliers for the survivors’ group, an open circle for the value over the [Q3 + 1.5 * (interquartile range)], and an asterisk for the value under the [Q1 − 3 * (interquartile range)]
Specific treatment indications, performed interventions, compliance to Rowlands’ algorithm, severity factors, and outcome
| Indications according to [ | Performed interventions | Compliance to the algorithm | Factors contributing to severity | Outcome | ||
|---|---|---|---|---|---|---|
| LD | ECLS | Yes/no | If no, criteria for deviation | |||
| Urgent LD | 2 | 0 | Yes | PHT, KF, ARDS, seizures | Survivor | |
| Urgent LD | 1 | 0 | No | > 24 h-delayed ECMO | Rapid worsening, ALF, KF, PHT, CPA | Non-survivor |
| VA-ECMO + LD | 0 | VA-ECMO | No combined LD | Viral co-infection | ||
| Urgent LD | 0 | 0 | No | No LD | ALF, KF, ARDS, PHT | Non-survivor |
| VA-ECMO + LD | 0 | VV → VA-ECMO | > 24 h-delayed ECMO | Viral co-infection | ||
| LD | 0 | 0 | No | No LD | Viral co-infection, PHT, ARDS | Non-survivor |
| VA-ECMO + LD | 0 | VV → VA-ECMO | > 24 h-delayed ECMO, no combined LD | ECMO complication: limb ischemia | ||
| Urgent LD | 1 | 0 | Yes | None | Survivor | |
| LD | 1 | 0 | ||||
| Urgent LD | 1 | 0 | Yes | Seizures | Survivor | |
| LD | 1 | 0 | Yes | Bacterial superinfection, viral co-infection | Survivor | |
| SIC | 0 | 0 | Yes | Viral co-infection | Survivor | |
| VA-ECMO + LD | 1 | VA-ECMO | No | LD on time, but > 24 h-delayed ECMO + LDa | PHT, ARDS, KF, bacterial superinfections | Non-survivor |
| ECMO complication: circuit thrombosis, extremities ischemia | ||||||
| VA-ECMO | 0 | VA-ECMO | Yes | PHT, KF, bacterial superinfection | Survivor | |
| SIC | 0 | 0 | Yes | None | Survivor | |
| Urgent LD | 0 | 0 | No | No LD | ARDS, KF, CPA | Non-survivor |
| VA-ECMO + LD | 0 | 0 | No ECMOa, no combined LD | |||
| Urgent LD | 0 | 0 | No | No LD | PHT, seizures | Survivor |
| Bacterial superinfection | ||||||
| VA-ECMO + LD | 0 | 0 | No | No ECMOa, no combined LD | Rapid worsening, ARDS, PHT, KF, bacterial superinfection | Non-survivor |
| LD | 1 | 0 | Yes | Bacterial superinfection, ARDS, HTP, KF | Survivor | |
| Urgent LD | 0 | 0 | No | No LD | Viral co-infection, seizures | Survivor |
| Urgent LD | 0 | 0 | No | > 24 h-delayed LD | HTP, KF, ALF, CPA, seizures, viral co-infection | Non-survivor |
| VA-ECMO + LD | 0 | VA-ECMO | > 24 h-delayed ECMOa, no combined LD | ECMO complication: failure of ECMO procedure | ||
| SIC | 0 | 0 | Yes | Bacterial superinfection, seizures, LTE | Survivor | |
| SIC | 0 | 0 | Yes | None | Survivor | |
| LD | 1 | 0 | Yes | None | Survivor | |
| VA-ECMO + LD | 0 | 0 | No | No VA-ECMOa, no combined LD | Rapid worsening, ARDS, PHT, bacterial superinfection | Non-survivor |
| Urgent LD | 1 | 0 | No | > 24 h-delayed LD | ARDS, CPA, PHT, KF, ALF, seizures | Non-survivor |
| VA-ECMO + LD | 0 | VA-ECMO | > 24 h-delayed ECMOa, no combined LD | Bacterial superinfections | ||
| Urgent LD | 1 | 0 | Yes | Bacterial superinfections | Survivor | |
In case of refractory CRF: ECMO + LF if [WBC > 50], ECMO ± LF if [WBC > 30], and standard respiratory ECMO for all other situations
aECLS not available on site: transfer to another center was required
bIndications refers to Rowlands’ algorithm [21]. In case of responsive CRF: urgent LD if [WBC > 100] or [WBC > 70 + CF + RF] or [WBC > 70 + (CF or RF) + PHT], LD if [WBC > 50 + (cardiac or respiratory deterioration)] and standard intensive care for all other situations
ARDS acute respiratory distress syndrome; ALF acute liver failure; KF kidney failure; CPA cardiopulmonary arrest; ECLS extracorporeal life support; LD leukodepletion; LTE life-threatening event; PHT pulmonary hypertension; SIC standard intensive care; VA-ECMO veno-arterial-extracorporeal membrane oxygenation; VV-ECMO veno-venous-ECMO